Systemic AAV8-Mediated Gene Therapy Drives Whole-Body Correction of Myotubular Myopathy in Dogs

Abstract : X-linked myotubular myopathy (XLMTM) results from MTM1 gene mutations and myotubularin deficiency. Most XLMTM patients develop severe muscle weakness leading to respiratory failure and death, typically within 2 years of age. Our objective was to evaluate the efficacy and safety of systemic gene therapy in the p.N155K canine model of XLMTM by performing a dose escalation study. A recombinant adeno-associated virus serotype 8 (rAAV8) vector expressing canine myotubularin (cMTM1) under the muscle-specific desmin promoter (rAAV8-cMTM1) was administered by simple peripheral venous infusion in XLMTM dogs at 10 weeks of age, when signs of the disease are already present. A comprehensive analysis of survival, limb strength, gait, respiratory function, neurological assessment, histology, vector biodistribution, transgene expression, and immune response was performed over a 9-month study period. Results indicate that systemic gene therapy was well tolerated, prolonged lifespan, and corrected the skeletal musculature throughout the body in a dose-dependent manner, defining an efficacious dose in this large-animal model of the disease. These results support the development of gene therapy clinical trials for XLMTM.
Document type :
Journal articles
Complete list of metadatas

https://hal-univ-evry.archives-ouvertes.fr/hal-02179363
Contributor : Melissa Goddard <>
Submitted on : Wednesday, July 10, 2019 - 4:47:12 PM
Last modification on : Wednesday, August 21, 2019 - 11:02:06 AM

Links full text

Identifiers

Citation

David Mack, Karine Poulard, Melissa Goddard, Virginie Latournerie, Jessica Snyder, et al.. Systemic AAV8-Mediated Gene Therapy Drives Whole-Body Correction of Myotubular Myopathy in Dogs. Molecular Therapy, Nature Publishing Group, 2017, 25 (4), pp.839-854. ⟨10.1016/j.ymthe.2017.02.004⟩. ⟨hal-02179363⟩

Share

Metrics

Record views

37